Uterine sarcoma

Overview

Uterine sarcoma is a rare and aggressive form of cancer that develops in the muscular wall of the uterus (the myometrium) or in the supporting connective tissues of the uterus. It belongs to a broader group of cancers known as sarcomas, which arise from connective tissues such as muscle, fat, blood vessels, and cartilage throughout the body.

Uterine sarcoma is significantly less common than endometrial cancer (cancer of the womb lining), which accounts for the vast majority of uterine malignancies. Uterine sarcomas represent only about 3–7% of all cancers of the uterus, yet they tend to behave more aggressively and are associated with poorer outcomes, largely because they spread (metastasize) earlier and are frequently diagnosed at an advanced stage.

Each year, approximately 1–2 women per 100,000 are diagnosed with uterine sarcoma worldwide. The disease most often affects women between the ages of 40 and 60, with leiomyosarcoma — the most common subtype — typically diagnosed around the time of menopause.

Uterine sarcoma is not the same as endometrial (womb lining) cancer. It requires different diagnostic approaches and treatments, and confusing the two can lead to delays in appropriate care.

Types of Uterine Sarcoma

Uterine sarcoma is not a single disease but a group of related cancers classified according to the type of tissue from which they originate. The main subtypes are:

1. Leiomyosarcoma (LMS)

The most common subtype, accounting for approximately 40–60% of all uterine sarcomas. It arises from the smooth muscle cells of the uterine wall. Leiomyosarcoma is considered an aggressive cancer with a tendency to spread through the bloodstream, often to the lungs. It usually presents as a single large tumor within the uterine muscle.

2. Endometrial Stromal Sarcoma (ESS)

This type develops from the connective tissue (stroma) of the endometrium — the inner lining of the uterus. It is divided into:

• Low-grade ESS: Slow-growing, often diagnosed early, and generally has a favorable prognosis. These tumors frequently express hormone receptors.
• High-grade / undifferentiated endometrial sarcoma: More aggressive, faster-growing, and associated with worse outcomes.

3. Undifferentiated Uterine Sarcoma

These tumors do not resemble any normal uterine tissue and have no hormone receptors. They are rare but highly aggressive.

4. Uterine Adenosarcoma

A rare tumor containing a mixture of benign (non-cancerous) glandular elements and cancerous connective tissue. It generally — but not always — follows a less aggressive course.

Historical Note on Carcinosarcoma

Carcinosarcoma (malignant mixed Müllerian tumor) was once classified as a uterine sarcoma. It is now recognized as a type of de-differentiated endometrial carcinoma and is treated as such, though it remains one of the most aggressive uterine cancers.

Summary of Types

Causes and Risk Factors

The exact cause of uterine sarcoma remains unknown. Like most sarcomas, it results from genetic mutations occurring within muscle or connective tissue cells. However, several factors have been shown to increase a woman’s risk:

Established Risk Factors

• Previous radiation therapy to the pelvis. Women treated with pelvic radiation for another cancer (for example, cervical cancer) have an increased risk of developing uterine sarcoma, typically 10–25 years after treatment.
• Long-term tamoxifen use. Tamoxifen, used in breast cancer treatment and prevention, slightly increases the risk of uterine sarcoma in women taking it for 5 years or more. The absolute risk remains small, and the benefits of tamoxifen in breast cancer generally outweigh this risk.
• Inherited genetic conditions:
• Hereditary retinoblastoma (RB1 gene mutation)
• Li-Fraumeni syndrome (TP53 gene mutation)
• No confirmed inherited syndrome exists specifically for uterine sarcoma in the majority of patients; most cases occur sporadically.

Additional Associated Factors

• Age: Most cases occur in women over 40; risk rises with age.
• Ethnicity: Studies indicate African American women have a roughly two-fold higher risk of leiomyosarcoma compared with white women, for reasons that are not fully understood.
• Uterine fibroids (questionable association): Fibroids are extremely common, and uterine sarcoma is rare. Importantly, it is rarely proven that a fibroid transforms into sarcoma. Most leiomyosarcomas are thought to arise de novo (newly), not from existing benign fibroids.

Risk Factor Summary

Important distinction: Unlike endometrial cancer, uterine sarcoma is not strongly linked** to obesity, diabetes, or excess estrogen exposure.

How Does It Look

This section describes the appearance of uterine sarcoma — both with the naked eye (gross appearance), under the microscope, and on medical imaging. Understanding how the disease looks helps explain how it is detected and why it can be difficult to distinguish from benign conditions.

Gross (Macroscopic) Appearance

When a uterus containing a sarcoma is examined after surgical removal, certain features raise suspicion:

Leiomyosarcoma typically appears as:

• A single, large, fleshy mass (often over 10 cm) embedded in the muscle wall of the uterus.
• A soft, fleshy, “fish flesh” texture — quite different from the firm, whorled, rubbery consistency of a benign fibroid.
• Areas of hemorrhage (bleeding) and necrosis (tissue death) within the tumor, giving the cut surface a mottled red-brown and yellow appearance.
• Poorly defined borders — the tumor infiltrates into surrounding muscle rather than pushing it aside cleanly the way a fibroid does.
• The mass may bulge into the uterine cavity or protrude through the serosal (outer) surface.

Endometrial stromal sarcoma often appears as a soft, tan-yellow, worm-like (“worm plug”) growth pattern, infiltrating the myometrium and extending in tongue-like projections into blood vessels and lymphatic channels. It may form a polyp protruding into the uterine cavity.

Microscopic Appearance (Histology)

Under the microscope, pathologists look for a combination of the following features (often called the “Stanford criteria” for leiomyosarcoma):

• Cytologic atypia: Cancer cells appear abnormal — enlarged, irregular, darkly staining nuclei, and abundant dividing cells.
• High mitotic activity: A large number of cells actively dividing (counted as mitoses per high-power field). The threshold is typically ≥10 mitoses per 10 high-power fields for a leiomyosarcoma diagnosis.
• Coagulative tumor cell necrosis: zones of dead tumor cells with a particular pattern distinct from benign degenerative changes.

Low-grade endometrial stromal sarcoma cells resemble normal endometrial stroma but invade the muscle and vessels; testing for hormone receptors (estrogen and progesterone receptors) and markers such as CD10 helps confirm the type.

Appearance on Imaging

Because symptoms of uterine sarcoma overlap with far-more-common benign lumps, doctors usually first “see” a uterine sarcoma on imaging:

• Transvaginal ultrasound: a rapidly enlarging uterine mass with mixed solid and cystic (fluid-filled/degenerating) areas, irregular contours, and rich internal blood flow on Doppler study. A single dominant mass (rather than several well-defined fibroids) is more suspicious.
• MRI (magnetic resonance imaging): the best imaging tool. Suspicious features include a large solitary mass with ill-defined margins, heterogeneous high signal intensity on T2-weighted images, areas of hemorrhage/necrosis, and restricted diffusion on specialized sequences. MRI cannot definitively prove sarcoma, but it helps distinguish benign fibroids from concerning lesions.
• CT and PET-CT: used mainly after diagnosis to look for spread — particularly to the lungs, the most common site of distant metastasis.

A crucial clinical reality: In many women, uterine sarcoma is diagnosed only after surgery** — for example, after a hysterectomy performed for presumed fibroids. Pre-operative biopsy can miss the tumor because leiomyosarcoma grows within the muscle wall, not in the lining where sampling is easiest.

Symptoms

Uterine sarcoma often produces few or no symptoms in its early stages, and when symptoms do occur, they frequently mimic benign conditions — especially uterine fibroids. This overlap is one of the main reasons for delays in diagnosis. Tumors may also first be suspected based on unexplained rapid growth of a presumed fibroid.

Most Common Symptoms

1. Abnormal vaginal bleeding — the leading symptom:

• Postmenopausal bleeding (any bleeding after the menopause should always be investigated).
• Heavy, prolonged, or irregular periods in premenopausal women.
• Bleeding between periods or bleeding after sexual intercourse.

1. Pelvic pain or pressure:

• A dull ache, heaviness, cramping, or feeling of fullness in the lower abdomen or pelvis.
• Pain that progressively worsens is of particular concern.

1. A pelvic or abdominal mass:

• An enlarging lump that can sometimes be felt through the abdomen.
• Noticeable abdominal swelling or distension.

1. Abnormal vaginal discharge:

• Watery, blood-tinged, or foul-smelling discharge, which may signal tissue breakdown or infection of the tumor.

1. A “fibroid” that grows rapidly:

• Rapid growth of a presumed fibroid, particularly after the menopause (when fibroids should normally shrink), is a warning sign that warrants further evaluation. Note, however, that most rapidly growing uterine masses are still benign.

Symptoms from Pressure on Nearby Organs

As the tumor grows, it may press on surrounding structures, causing:

• Urinary symptoms: frequent urination, difficulty emptying the bladder, or urinary retention.
• Bowel symptoms: constipation, change in bowel habits, or a feeling of incomplete evacuation.
• Back or leg pain and leg swelling if nerves or blood vessels are compressed.

Symptoms of Advanced or Metastatic Disease

If the cancer has spread beyond the uterus, additional symptoms may include:

• Persistent cough or shortness of breath (lung metastases — the most common distant site).
• Pain in the bones, or swelling/pain elsewhere in the abdomen.
• General symptoms: unintentional weight loss, extreme fatigue, loss of appetite.

When to See a Doctor — Warning Signs Checklist

✅ Consult a doctor promptly if you experience:

• Any vaginal bleeding after menopause — this always requires investigation
• Periods that have become significantly heavier, longer, or irregular
• A new or enlarging lump in the pelvis or abdomen
• Persistent pelvic pain or pressure lasting several weeks
• Unusual vaginal discharge, especially if blood-stained or foul-smelling
• Noticeable growth of a known fibroid after menopause
• Unexplained weight loss, fatigue, or persistent cough

Remember:** None of these symptoms automatically mean cancer — most women with them will turn out to have a benign condition. However, only proper medical evaluation can make that determination.

Diagnosis

Diagnosing uterine sarcoma can be challenging. There is no reliable screening test, and pre-operative diagnosis is often difficult because the tumor hides within the muscular wall.

Steps in the Diagnostic Process

1. Medical history and pelvic examination. The doctor assesses symptoms, risk factors, and performs a bimanual examination to feel the size, shape, and mobility of the uterus.
2. Transvaginal ultrasound. Usually the first imaging study — evaluates uterine size, masses, blood flow, and endometrial thickness.
3. MRI of the pelvis. Helps characterize the lesion and distinguish between benign fibroids and suspicious masses; also maps local extent.
4. Endometrial biopsy (pipelle) or hysteroscopy with sampling. Samples the lining of the uterus. Important caveat: leiomyosarcomas are often missed by endometrial biopsy because they grow in the muscle layer — a negative biopsy does not exclude sarcoma. Biopsy is more likely to detect ESS, which involves the uterine cavity.
5. Definitive diagnosis — surgical pathology. The gold standard is microscopic examination of tissue obtained by hysterectomy (removal of the uterus) or, rarely, targeted biopsy of the mass. Only histology can confirm the diagnosis, the subtype, the grade, and the stage.
6. Staging investigations (after diagnosis is established):

• CT scan of the chest, abdomen, and pelvis — to detect lung and abdominal spread.
• PET-CT — in selected cases for metabolic imaging of metastases.
• Blood tests, including baseline counts and organ function before treatment.

Staging

Staging describes how far the cancer has spread and guides treatment and prognosis. Uterine sarcomas are staged using the FIGO (International Federation of Gynecology and Obstetrics) system.

FIGO Staging for Leiomyosarcoma and Endometrial Stromal Sarcoma

Staging matters greatly: tumors confined to the uterus (Stage I) have a markedly better outlook than those that have spread.

Treatment

Treatment is individualized based on the type, stage, and grade of the tumor, as well as the patient’s general health and preferences. Management should be carried out by a multidisciplinary team, ideally at a center experienced in sarcoma care.

1. Surgery — the Mainstay of Treatment

• Total hysterectomy with bilateral salpingo-oophorectomy (removal of the uterus, cervix, ovaries, and fallopian tubes) is the standard primary operation.
• Care is taken to remove the uterus intact, avoiding tumor fragmentation or spillage.
• Morcellation (cutting the uterus into small pieces for minimally invasive removal) is contraindicated when sarcoma is known or suspected, because it can spread tumor cells throughout the abdomen. This is why preoperative suspicion is so important.
• Lymph node removal (lymphadenectomy) is not routinely recommended in leiomyosarcoma unless nodes are visibly enlarged, as spread via lymph nodes is uncommon in LMS.
• In selected young women with low-grade endometrial stromal sarcoma or very early disease, organ-sparing approaches may occasionally be considered under expert supervision, but this is exceptional.
• For advanced disease, cytoreductive surgery (removing as much tumor as possible) may be offered in carefully selected cases.

2. Radiation Therapy

• External-beam pelvic radiotherapy may be used after surgery to reduce the risk of local recurrence in the pelvis, although it has not been proven to prolong overall survival in uterine leiomyosarcoma.
• It is more commonly used for endometrial stromal sarcoma (which recurs locally more often) and for symptom relief in advanced disease.

3. Chemotherapy

Used mainly for advanced, recurrent, or metastatic disease, particularly leiomyosarcoma:

• Doxorubicin — the most established single agent.
• Gemcitabine plus docetaxel — a commonly used combination.
• Dacarbazine — active in LMS.
• The benefit of adjuvant (post-surgical) chemotherapy in early-stage disease remains uncertain; decisions are individualized.

4. Hormonal Therapy

Particularly important for low-grade endometrial stromal sarcoma, which typically expresses estrogen and progesterone receptors:

• Progestins (e.g., megestrol acetate, medroxyprogesterone acetate)
• Aromatase inhibitors (e.g., letrozole, anastrozole)
• Important: Estrogen replacement therapy and tamoxifen are generally avoided in women with a history of ESS, as they can stimulate tumor growth.

5. Targeted Therapy and Newer Options

• Pazopanib — an oral targeted agent (tyrosine kinase inhibitor) approved for advanced soft-tissue sarcomas.
• Trabectedin — active in selected cases of advanced leiomyosarcoma.
• Participation in clinical trials is strongly encouraged, given the rarity of the disease and the need for better therapies.

Treatment by Situation — Summary

Prognosis

The outlook for uterine sarcoma depends chiefly on stage at diagnosis, but also on tumor type, size, grade, mitotic activity, and whether the tumor was removed completely.

General Prognostic Points

• Uterine sarcoma has a higher recurrence rate than endometrial cancer — recurrence can occur even after complete surgical removal of a Stage I tumor, sometimes many years later (this is especially true of low-grade ESS, which may recur 10–20 years after diagnosis).
• The lungs are the most frequent site of distant recurrence.
• Reported five-year relative survival rates vary by stage and subtype; approximations for uterine leiomyosarcoma are in the range of 50–75% for Stage I, falling substantially for Stages III–IV. Low-grade ESS has considerably better long-term survival in early stages.

Factors Associated with Better Prognosis

• Diagnosis at Stage I (tumor confined to the uterus)
• Smaller tumor size (under 5 cm)
• Low mitotic count and low grade
• Complete surgical removal without tumor spillage
• Hormone receptor positivity (in ESS) enabling hormonal treatment
• Younger age and good general health

Factors Associated with Poorer Prognosis

• Large tumor size and high mitotic activity
• Spread beyond the uterus at diagnosis
• Tumor disruption or morcellation during surgery
• High-grade or undifferentiated histology

Follow-up is essential.** Due to the risk of late recurrence, women treated for uterine sarcoma require long-term surveillance with regular pelvic examinations and imaging (typically chest imaging because of lung metastasis risk), often for 10 years or more.

Prevention and Screening

Currently, there is no proven way to prevent uterine sarcoma, and no screening test exists for early detection in the general population. Nevertheless, certain sensible measures may reduce risk or facilitate earlier detection:

• Careful consideration of tamoxifen: Women taking tamoxifen should report any abnormal vaginal bleeding promptly. The decision to use tamoxifen is always individualized, balancing breast cancer benefits against uterine risks.
• Avoid unnecessary irradiation and judicious use of pelvic radiotherapy in younger patients where alternative treatments exist.
• Prompt evaluation of symptoms: Seeking medical attention for postmenopausal bleeding, unusual discharge, or pelvic changes enables earlier diagnosis.
• Genetic counseling for women with a personal or family history of retinoblastoma or Li-Fraumeni syndrome.
• Cautious management of presumed fibroids that grow rapidly or behave atypically — especially after menopause.

Living With Uterine Sarcoma

A diagnosis of uterine sarcoma affects every aspect of life. Beyond medical treatment, patients benefit from comprehensive support:

• Psychological support: counseling, peer support groups, and psycho-oncology services help manage anxiety, fear of recurrence, and treatment-related stress.
• Managing surgical menopause: women who have their ovaries removed before natural menopause may experience hot flashes, mood changes, and bone density loss. Hormone replacement therapy must be discussed carefully with the oncologist — it is often avoided in hormone-sensitive tumors.
• Physical recovery: gradual return to activity after surgery, pelvic floor physiotherapy where needed, and management of treatment side effects (fatigue, nausea, blood count changes).
• Sexual health: changes after hysterectomy and menopause can affect intimacy; specialist guidance is available and worthwhile.
• Long-term surveillance: attending all follow-up appointments and reporting new symptoms promptly.
• Practical matters: work, finances, and family responsibilities may need adjustment during treatment — oncology social workers can help.

Asking for support is a sign of strength, and many women go on to lead full, active lives after treatment.

Key Takeaways

• Uterine sarcoma is a rare cancer of the uterine muscle or connective tissue, distinct from the more common endometrial cancer.
• It often presents with abnormal bleeding, pelvic pain, and a rapidly enlarging uterine mass, but symptoms mimic benign fibroids, delaying diagnosis.
• “How it looks” — a large, fleshy, infiltrative mass with hemorrhage and necrosis — differs from benign fibroids, but definitive diagnosis requires microscopic examination after surgery.
• Surgery (intact removal of the uterus) is the cornerstone of treatment; morcellation must be avoided.
• Prognosis depends mainly on stage; even early-stage disease requires long-term follow-up because of recurrence risk.
• Any postmenopausal bleeding or unusually behaving pelvic mass should always be medically evaluated.

References

1. Benson, C. and Miah, A.B. (2017) ‘Uterine sarcoma — current perspectives’, International Journal of Women’s Health, 9, pp. 597–606.
2. Berek, J.S. and Hacker, N.F. (eds.) (2020) Berek & Hacker’s Gynecologic Oncology. 7th edn. Philadelphia: Wolters Kluwer.
3. D’Angelo, E. and Prat, J. (2010) ‘Uterine sarcomas: a review’, Gynecologic Oncology, 116(1), pp. 131–139.
4. FIGO Committee on Gynecologic Oncology (2009) ‘FIGO staging for uterine sarcomas’, International Journal of Gynaecology and Obstetrics, 104(3), pp. 179–180.
5. George, S., Serrano, C., Hensley, M.L. and Ray-Coquard, I. (2018) ‘Soft tissue and uterine leiomyosarcoma’, Journal of Clinical Oncology, 36(2), pp. 144–150.
6. Mbatani, N., Olawaiye, A.B. and Prat, J. (2018) ‘Uterine sarcomas’, International Journal of Gynaecology and Obstetrics, 143(Suppl 2), pp. 51–58.
7. National Comprehensive Cancer Network (NCCN) (2023) NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms. Plymouth Meeting, PA: NCCN.
8. Rauh-Hain, J.A. and del Carmen, M.G. (2013) ‘Endometrial stromal sarcoma: a systematic review’, Obstetrics & Gynecology, 122(3), pp. 676–683.
9. Robson, M.E., Lynch, H.T. and Foulkes, W.D. (eds.) (2021) Principles of Gynecologic Oncology. 8th edn. London: Elsevier.
10. Trope, C.G., Abeler, V.M. and Kristensen, G.B. (2012) ‘Diagnosis and treatment of sarcoma of the uterus: a review’, Acta Oncologica, 51(6), pp. 694–705.
11. WHO Classification of Tumours Editorial Board (2020) Female Genital Tumours: WHO Classification of Tumours. 5th edn. Lyon: International Agency for Research on Cancer.

Disclaimer: This article is intended for general informational purposes only and does not substitute professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or symptoms.